In summary, the current study is the first to suggest that NOTCH4-MUT is related to strengthened tumor immunogenicity and inflamed antitumor immunity, which led to a better response and prolonged OS in cancer patients treated with ICI therapy, indicating that NOTCH4-MUT could be considered a potential predictive biomarker for ICI therapy. This evidence concerns the gene NOTCH4 and cancer.